标题
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
作者
关键词
-
出版物
NATURE REVIEWS DRUG DISCOVERY
Volume 16, Issue 12, Pages 843-862
出版商
Springer Nature
发表日期
2017-11-06
DOI
10.1038/nrd.2017.201
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
- (2017) Julian Panés et al. GUT
- Janus kinase inhibition for immunosuppression in solid organ transplantation: Is there a role in complex immunologic challenges?
- (2017) Cody A. Moore et al. HUMAN IMMUNOLOGY
- Impact of tofacitinib treatment on human B-cells in vitro and in vivo
- (2017) Marta Rizzi et al. JOURNAL OF AUTOIMMUNITY
- Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib
- (2017) Brett King et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- (2017) Lucy Y. Liu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tofacitinib for the treatment of alopecia areata and variants in adolescents
- (2017) Brittany G. Craiglow et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
- (2017) Peter C. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Malignancy and Janus Kinase Inhibition
- (2017) Padmapriya Sivaraman et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- A case of refractory dermatomyositis responsive to tofacitinib
- (2017) Julie J. Paik et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
- (2017) Josef S. Smolen et al. Arthritis & Rheumatology
- Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate
- (2017) A. J. Kivitz et al. Arthritis & Rheumatology
- Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis
- (2017) Mark C. Genovese et al. Arthritis & Rheumatology
- Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
- (2017) Roy Fleischmann et al. Arthritis & Rheumatology
- Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition
- (2016) Jean-Baptiste Telliez et al. ACS Chemical Biology
- Reversal of Alopecia Universalis by Tofacitinib: A Case Report
- (2016) Morton Scheinberg et al. ANNALS OF INTERNAL MEDICINE
- Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques
- (2016) Philip G Conaghan et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib for polyarteritis nodosa: a tailored therapy
- (2016) Doron Rimar et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings
- (2016) Mark C Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
- (2016) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study
- (2016) V.J. Ludbrook et al. BRITISH JOURNAL OF DERMATOLOGY
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
- (2016) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation
- (2016) Tomohiro Koga et al. CLINICAL IMMUNOLOGY
- Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis
- (2016) Roland Martin et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Beryllium-induced lung disease exhibits expression profiles similar to sarcoidosis
- (2016) Li Li et al. EUROPEAN RESPIRATORY JOURNAL
- Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1
- (2016) Jason G. Kettle et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2
- (2016) Jason G. Kettle et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Phosphoproteomic Analyses of Interleukin 2 Signaling Reveal Integrated JAK Kinase-Dependent and -Independent Networks in CD8 + T Cells
- (2016) Sarah H. Ross et al. IMMUNITY
- Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies
- (2016) Roy Fleischmann et al. International Journal of Rheumatic Diseases
- Tofacitinib Response in Juvenile Idiopathic Arthritis (JIA) and Collagenous Colitis
- (2016) Bryon Tseng et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study
- (2016) James Krueger et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food
- (2016) Manisha Lamba et al. JOURNAL OF CLINICAL PHARMACOLOGY
- JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation
- (2016) Wataru Amano et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis
- (2016) Jashin J. Wu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy of tofacitinib in treatment of alopecia universalis in two patients
- (2016) A.K. Gupta et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
- (2016) Sally Wenzel et al. LANCET
- Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus
- (2016) L Kahl et al. LUPUS
- Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling
- (2016) Geoffrey A Smith et al. Nature Chemical Biology
- Baricitinib in Patients with Refractory Rheumatoid Arthritis
- (2016) Mark C. Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Network pharmacology of JAK inhibitors
- (2016) Devapregasan Moodley et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor
- (2016) Christina Charles-Schoeman et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist
- (2016) Christina Charles-Schoeman et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Long-term activation of the innate immune system in atherosclerosis
- (2016) Anette Christ et al. SEMINARS IN IMMUNOLOGY
- Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells
- (2016) Robert E. Chapin et al. TOXICOLOGICAL SCIENCES
- Relationship Between Baseline and Early Changes in C-Reactive Protein and Interleukin-6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis
- (2016) Jianmei Wang et al. ARTHRITIS CARE & RESEARCH
- Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease
- (2016) Malgorzata Szelag et al. Oncotarget
- Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis
- (2016) Drew J. B. Kurtzman et al. JAMA Dermatology
- Topical Ruxolitinib for the Treatment of Alopecia Universalis
- (2016) Brittany G. Craiglow et al. JAMA Dermatology
- The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis
- (2016) Philip J. Mease et al. Arthritis & Rheumatology
- Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- (2016) Mark C. Genovese et al. Arthritis & Rheumatology
- A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy
- (2016) Joel M. Kremer et al. Arthritis & Rheumatology
- Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments
- (2016) Fenglong Xie et al. Arthritis & Rheumatology
- Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction
- (2016) Yasuko Furumoto et al. Arthritis & Rheumatology
- Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
- (2016) Nicola A Hanania et al. Lancet Respiratory Medicine
- Molecular mechanisms of pruritus
- (2016) J. Meng et al. Current Research in Translational Medicine
- Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients
- (2015) F. Vincenti et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
- (2015) Christina Charles-Schoeman et al. ANNALS OF THE RHEUMATIC DISEASES
- The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
- (2015) Kevin L Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors
- (2015) W Gao et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
- (2015) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-22: Immunobiology and Pathology
- (2015) Jarrod A. Dudakov et al. Annual Review of Immunology
- The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
- (2015) John J. O'Shea et al. Annual Review of Medicine
- A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis
- (2015) K. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
- (2015) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor
- (2015) N. Punwani et al. BRITISH JOURNAL OF DERMATOLOGY
- The role of lymphocytes in the development and treatment of alopecia areata
- (2015) Hongwei Guo et al. Expert Review of Clinical Immunology
- Tofacitinib for the treatment of moderate-to-severe psoriasis
- (2015) Andrea Chiricozzi et al. Expert Review of Clinical Immunology
- The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling
- (2015) Wataru Amano et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases
- (2015) Luc J. Farmer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Super-enhancers delineate disease-associated regulatory nodes in T cells
- (2015) Golnaz Vahedi et al. NATURE
- Type I/II cytokines, JAKs and new strategies for treating autoimmune diseases
- (2015) Daniella M. Schwartz et al. Nature Reviews Rheumatology
- Preliminary response to Janus kinase inhibition with baricitinib in chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE)
- (2015) G Montealegre et al. Pediatric Rheumatology
- Cardiovascular risk factor management in patients with RA compared to matched non-RA patients
- (2015) Evo Alemao et al. RHEUMATOLOGY
- Tofacitinib With Methotrexate in Third-Line Treatment of Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Trial
- (2015) Vibeke Strand et al. ARTHRITIS CARE & RESEARCH
- Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
- (2015) Vibeke Strand et al. ARTHRITIS RESEARCH & THERAPY
- Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
- (2015) Vibeke Strand et al. ARTHRITIS RESEARCH & THERAPY
- Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial
- (2015) Joel M Kremer et al. ARTHRITIS RESEARCH & THERAPY
- Tofacitinib Citrate for the Treatment of Vitiligo
- (2015) Brittany G. Craiglow et al. JAMA Dermatology
- Disease Activity in Rheumatoid Arthritis and the Risk of Cardiovascular Events
- (2015) D. H. Solomon et al. Arthritis & Rheumatology
- A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
- (2015) Roy M. Fleischmann et al. Arthritis & Rheumatology
- VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib
- (2015) Christina Charles-Schoeman et al. Arthritis & Rheumatology
- An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy
- (2015) Vijay U. Rao et al. Arthritis & Rheumatology
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- (2015) Ali Jabbari et al. EBioMedicine
- Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol
- (2015) Eric R. Goedken et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia
- (2014) Lisa Pieri et al. AMERICAN JOURNAL OF HEMATOLOGY
- Ibrutinib for the Treatment of Mantle Cell Lymphoma
- (2014) A. F. Herrera et al. CLINICAL CANCER RESEARCH
- A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
- (2014) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- IL-9 and its receptor are predominantly involved in the pathogenesis of UC
- (2014) Nancy Nalleweg et al. GUT
- The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers
- (2014) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Inhibition of TYK2 and JAK1 Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis by Inhibiting IL-22 and the IL-23/IL-17 Axis
- (2014) Melissa G. Works et al. JOURNAL OF IMMUNOLOGY
- Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634
- (2014) Christel J. Menet et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
- (2014) James D. Clark et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
- (2014) J. Wollenhaupt et al. JOURNAL OF RHEUMATOLOGY
- Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy
- (2014) A. J. Gonzales et al. JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS
- TH9 cells that express the transcription factor PU.1 drive T cell–mediated colitis via IL-9 receptor signaling in intestinal epithelial cells
- (2014) Katharina Gerlach et al. NATURE IMMUNOLOGY
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- (2014) Luzhou Xing et al. NATURE MEDICINE
- IL-6 biology: implications for clinical targeting in rheumatic disease
- (2014) Leonard H. Calabrese et al. Nature Reviews Rheumatology
- JAK–cytokine receptor recognition, unboxed
- (2014) Randall McNally et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Tofacitinib versus Methotrexate in Rheumatoid Arthritis
- (2014) Eun Bong Lee et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib
- (2014) Thorsten Hornung et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
- (2014) Hector G. Ortega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Advances in kinase targeting: current clinical use and clinical trials
- (2014) Mathias Rask-Andersen et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials
- (2014) John D Isaacs et al. ARTHRITIS RESEARCH & THERAPY
- Lipid Profile Changes in Patients With Chronic Inflammatory Arthritis Treated With Biologic Agents and Tofacitinib in Randomized Clinical Trials: A Systematic Review and Meta-Analysis
- (2014) Alejandro Souto et al. Arthritis & Rheumatology
- Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
- (2013) Joel Kremer et al. ANNALS OF INTERNAL MEDICINE
- Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study
- (2013) Désirée van der Heijde et al. ARTHRITIS AND RHEUMATISM
- Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
- (2013) Ying He et al. BMC MUSCULOSKELETAL DISORDERS
- Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
- (2013) L. Van Rompaey et al. JOURNAL OF IMMUNOLOGY
- Reversal of CD8 T-Cell–Mediated Mucocutaneous Graft-Versus-Host-Like Disease by the JAK Inhibitor Tofacitinib
- (2013) Naoko Okiyama et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue
- (2013) J M Leung et al. Mucosal Immunology
- Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib
- (2013) Rowan Wathes et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAKs and STATs in Immunity, Immunodeficiency, and Cancer
- (2013) John J. O'Shea et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-6: From basic biology to selective blockade of pro-inflammatory activities
- (2013) Jürgen Scheller et al. SEMINARS IN IMMUNOLOGY
- A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis
- (2013) Sallie B. Cosgrove et al. VETERINARY DERMATOLOGY
- Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year
- (2012) F. Vincenti et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
- (2012) Wolfgang Hueber et al. GUT
- SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis
- (2012) B. Madan et al. JOURNAL OF IMMUNOLOGY
- Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis
- (2012) Anthony D. William et al. JOURNAL OF MEDICINAL CHEMISTRY
- Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis
- (2012) Naresh Punwani et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/Stat6 signal transduction pathway: Implication for atopic dermatitis
- (2012) Lei Bao et al. MOLECULAR IMMUNOLOGY
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib (CP-690,550), a Janus Kinase Inhibitor for Dry Eye Disease
- (2012) Shiao Hui (Melissa) Liew et al. OPHTHALMOLOGY
- Origin and Function of Circulating Plasmablasts during Acute Viral Infections
- (2012) Katja Fink Frontiers in Immunology
- Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial
- (2011) J. M. Kremer et al. ANNALS OF THE RHEUMATIC DISEASES
- Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling
- (2011) D. A. Hume et al. BLOOD
- Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors
- (2011) Claude Haan et al. CHEMISTRY & BIOLOGY
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
- (2011) Kamran Ghoreschi et al. JOURNAL OF IMMUNOLOGY
- FLT3 as a therapeutic target in AML: still challenging after all these years
- (2010) T. Kindler et al. BLOOD
- Cardiovascular Disease and Risk Factors in Patients with Psoriasis and Psoriatic Arthritis
- (2010) A.-M. TOBIN et al. JOURNAL OF RHEUMATOLOGY
- An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis
- (2010) Michael E. Weinblatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis
- (2010) Chi Chiu Mok et al. ARTHRITIS CARE & RESEARCH
- Systemic lupus erythematosus and the risk of cardiovascular disease: Results from the nurses' health study
- (2009) A. Elisabeth Hak et al. ARTHRITIS AND RHEUMATISM
- Revisiting Crohn's disease as a primary immunodeficiency of macrophages: Figure 1.
- (2009) Jean-Laurent Casanova et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
- Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
- (2008) Marc E. Rothenberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis
- (2008) Anthony J Milici et al. ARTHRITIS RESEARCH & THERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started